40 results on '"Tassinari, Elisa"'
Search Results
2. The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study
3. Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study
4. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
5. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis
6. TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
7. Safety issues in nutraceutical exploitation of Chlorella vulgaris, Arthrospira Platensis and Scenedesmus sp. microalgae
8. First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer’s Disease
9. Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma
10. Appropriateness of Mini-Invasive Approaches for Nausea and Vomiting Refractory to Medical Therapy in Palliative Care Setting: A Case Report
11. What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it?
12. Tassinari, Elisa
13. Integrating a quinone substructure into histone deacetylase inhibitors to cope with Alzheimer's disease and cancer.
14. Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial
15. Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report
16. TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
17. Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?
18. How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?
19. From Monoamine Oxidase Inhibition to Antiproliferative Activity: New Biological Perspectives for Polyamine Analogs
20. Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study
21. Metabolic pseudo-progression in a patient with metastatic KIT exon 11 GIST after one month of first-line imatinib: a case report
22. An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma
23. Prostate cancer and novel pharmacological treatment options–what’s new for 2022?
24. Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis
25. Integrating a quinone substructure into histone deacetylase inhibitors to cope with Alzheimer's disease and cancerElectronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d4md00175c
26. The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy
27. Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers
28. Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study
29. Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis
30. A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.
31. Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
32. Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw
33. PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?
34. Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer
35. The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?
36. Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study
37. The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy
38. A GABAB receptor antagonist rescues functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder
39. Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study
40. A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.